Lifeboat Foundation

The gene editing system CRISPR-Cas9 makes breaks in DNA strands that are repaired by cells—a process that can be hard to control, resulting in unwanted genetic changes. Researchers at the Massachusetts Institute of Technology and the University of California, San Francisco (UCSF) designed an alternative technology that changes gene expression without damaging DNA, and they believe it could be useful for both research and drug development.

The researchers used their system, dubbed CRISPRoff and CRISPRon, to induce pluripotent stem cells to transform into neurons. They also used it to silence the gene that makes the protein Tau, which has been implicated in Alzheimer’s disease. They described their research in the journal Cell.

The MIT and UCSF researchers started by creating a machine made of a protein and small RNAs that guided it to specific spots on strands of DNA. The machine adds “methyl groups” to genes to silence their expression. The technology can also reverse the process, turning the genes back on by removing the methyl groups.

Like something straight out of a pulpy sci-fi horror flick, researchers at Tufts University and the University of Vermont (UVM) have engineered a new generation of living robots they call Xenobots, which demonstrate cooperative swarm activity while collecting piles of micro particles.

Last year, this same team of scientists and biologists created tiny self-healing bio-machines that exhibited movement, payload pushing abilities, and a sort of hive mentality. The blueprints for creating these biological bots, which technically aren’t a typical robot or a catalogued animal species, but instead are more akin to a distinct class of unique artifact that acts as a living, programmable organism.

In a recent study led by the University of Bristol, scientists have shown how to simultaneously harness multiple forms of regulation in living cells to strictly control gene expression and open new avenues for improved biotechnologies.

Engineered microbes are increasingly being used to enable the sustainable and clean production of chemicals, medicines and much more. To make this possible, bioengineers must control when specific sets of genes are turned on and off to allow for careful regulation of the biochemical processes involved.

Their findings are reported in the journal Nature Communications.

Using Artificial Intelligence And Plant Biology, To Re-Connect People and Plants, For Health & Wellness — Dr. Lee Chae, Ph.D., Co-Founder & CTO, Brightseed.

Dr. Lee Chae, Ph.D., is a Co-Founder and Chief Technology Officer at Brightseed, a novel life sciences company, merging the tools of plant biology and artificial intelligence, with a goal of enabling a healthier future by re-illuminating and re-activating the connections between people and plants.

Continue reading “Dr. Lee Chae — Co-Founder / CTO, Brightseed — Re-Connect People and Plants, For Health & Wellness” »

A team of polymer science and engineering researchers at the University of Massachusetts Amherst has demonstrated for the first time that the positions of tiny, flat, solid objects integrated in nanometrically thin membranes—resembling those of biological cells—can be controlled by mechanically varying the elastic forces in the membrane itself. This research milestone is a significant step toward the goal of creating ultrathin flexible materials that self-organize and respond immediately to mechanical force.

The team has discovered that rigid solid plates in biomimetic fluid membranes experience interactions that are qualitatively different from those of biological components in cell membranes. In cell membranes, fluid domains or adherent viruses experience either attractions or repulsions, but not both, says Weiyue Xin, lead author of the paper detailing the research, which recently appeared in Science Advances. But in order to precisely position solid objects in a membrane, both attractive and repulsive forces must be available, adds Maria Santore, a professor of polymer science and engineering at UMass. In the Santore Lab at UMass, Xin used giant unilamellar vesicles, or GUVs, which are cell-like membrane sacks, to probe the interactions between solid objects in a thin, sheet-like material. Like biological cells, GUVs have fluid membranes and form a nearly spherical shape. Xin modified the GUVs so that the membranes included tiny, solid, stiff plate-like masses.

A patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.

The gene editing research was conducted at the Perelman School of Medicine in the University of Pennsylvania. Results of the case, detailed in a paper published April 1 in Nature Medicine, show that the treatment led to marked changes at the fovea, the most important point of human central vision.

In the international clinical trial, participants received an intraocular injection of an antisense oligonucleotide called sepofarsen. This short RNA molecule works by increasing normal CEP290 protein levels in the eye’s photoreceptors and improving retinal function under day vision conditions.

A breakthrough in synthetic biology could shed new light on mechanisms controlling the most basic processes of life.

Gene editing has shown great promise as a non-heritable way to treat a wide range of conditions, including many genetic diseases and more recently, even COVID-19. But could a version of the CRISPR gene-editing tool also help deliver long-lasting pain relief without the risk of addiction associated with prescription opioid drugs?

In work recently published in the journal Science Translational Medicine, researchers demonstrated in mice that a modified version of the CRISPR system can be used to “turn off” a gene in critical neurons to block the transmission of pain signals [1]. While much more study is needed and the approach is still far from being tested in people, the findings suggest that this new CRISPR-based strategy could form the basis for a whole new way to manage chronic pain.

This novel approach to treating chronic pain occurred to Ana Moreno, the study’s first author, when she was a Ph.D. student in the NIH-supported lab of Prashant Mali, University of California, San Diego. Mali had been studying a wide range of novel gene-and cell-based therapeutics. While reading up on both, Moreno landed on a paper about a mutation in a gene that encodes a pain-enhancing protein in spinal neurons called NaV1.7.

**Five years ago, scientists created a single-celled synthetic organism that, with only 473 genes, was the simplest living cell ever known.** However, this bacteria-like organism behaved strangely when growing and dividing, producing cells with wildly different shapes and sizes.

Now, scientists have identified seven genes that can be added to tame the cells’ unruly nature, causing them to neatly divide into uniform orbs. This achievement, a collaboration between the J. Craig Venter Institute (JCVI), the National Institute of Standards and Technology (NIST) and the Massachusetts Institute of Technology (MIT) Center for Bits and Atoms, was described in the journal Cell.

Identifying these genes is an important step toward engineering synthetic cells that do useful things. Such cells could act as small factories that produce drugs, foods and fuels; detect disease and produce drugs to treat it while living inside the body; and function as tiny computers.

Continue reading “Scientists create simple synthetic cell that grows and divides normally” »